• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Differences in the inflammatory response and outcome among hospitalized patients during different waves of the COVID-19 pandemic

tetano

Editor, Senior Moderator
Front Immunol


. 2025 Mar 27:16:1545181.
doi: 10.3389/fimmu.2025.1545181. eCollection 2025. Differences in the inflammatory response and outcome among hospitalized patients during different waves of the COVID-19 pandemic

Violeta Briciu[SUP] 1 2 [/SUP], Daniel-Corneliu Leucuta[SUP] 3 [/SUP], Monica Muntean[SUP] 1 2 [/SUP], Amanda Radulescu[SUP] 1 2 [/SUP], Cristina Cismaru[SUP] 1 2 [/SUP], Adriana Topan[SUP] 1 2 [/SUP], Lucia Herbel[SUP] 2 [/SUP], Melinda Horvat[SUP] 1 2 [/SUP], Mirela Flonta[SUP] 2 [/SUP], Mihai Calin[SUP] 2 [/SUP], Roxana Dobrota[SUP] 2 [/SUP], Mihaela Lupse[SUP] 1 2 [/SUP]



Affiliations
Abstract

Introduction: The aim of this study was to evaluate differences in inflammatory biomarkers and their association with outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19) during four pandemic waves determined by different SARSCoV- 2 variants of concern. We explored if laboratory biomarkers of inflammation adjusted to patients' comorbidities, age, and vaccination status correlated with severity and mortality.
Methods: A retrospective study on 8,614 consecutive hospitalized COVID-19 patients was conducted in a Romanian hospital on a 3-year interval (February 2020 to May 2023). Data collected included demographics, duration of hospitalization, comorbidities, vaccination status, COVID-19 severity, outcome, and markers of inflammation from the first blood test performed at admittance [C-reactive protein (CRP), fibrinogen, ferritin, lactate dehydrogenase (LDH), procalcitonin (PCT), IL-6, D-dimer, and complete blood count]. Systemic inflammatory indexes like neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), neutrophil-to-platelet ratio (NPR), Systemic Immune-Inflammation Index (SII), and systemic inflammation response index (SIRI) were calculated.
Results: The Delta wave, characterized by the longest hospitalizations and the highest rates of severe cases and mortality, showed significant elevations in inflammatory biomarkers. CRP, fibrinogen, ferritin, IL-6, D-dimer, and LDH increased in their median values from the Wuhan to Delta wave and decreased in the Omicron wave, except PCT, which increased from the Alpha to Omicron wave. Leukocytes and neutrophils increased in their median values from the Wuhan to Delta wave and decreased in the Omicron wave, while an inverse pattern can be observed for lymphocytes, monocytes, and basophils. The best inflammatory biomarkers for predicting severe/critical COVID-19 were CRP, dNLR, LDH, and NLR (cut-off of 3.41 mg/dL, 3.05, 262 U/L, and 4.5, respectively), while for predicting death outcomes, the best biomarkers were dNLR, NLR, LDH, and NPR (cut-off of 3.6, 4.9, 278 U/L, and 0.02, respectively). For all these biomarkers, the areas under the curve (AUCs) surpassed 0.8. In the multivariate analysis, the highest adjusted OR for death was described for dNLR (8.46), NLR (7.59), LDH (5.99), and NPR (5.5), while increased lymphocytes decreased the highest adjusted OR for death (0.16).
Conclusion: The study, underscoring the dynamic nature of COVID-19, brings a detailed analysis of biomarker trends that could provide valuable information for the early identification of patients at risk for severe outcomes, allowing for timely interventions.

Keywords: COVID-19; disease severity; inflammatory biomarkers; mortality; pandemic waves; systemic inflammatory indexes.

 
Back
Top Bottom